Aggressive Lymphomas
News
FDA places full, partial holds on durvalumab trials
The US Food and Drug Administration (FDA) has placed a partial clinical hold on 5 trials and a full clinical hold on 1 trial of the anti-PD-L1...
News
Nanocarriers could treat leukemia, lymphoma and improve HSCT
Researchers say they have created nanoparticles loaded with messenger RNA (mRNA) that can give cells the ability to fight cancers and other...
News
CNS lymphoma responds to CAR T-cell therapy
Researchers have reported the first known case of central nervous system (CNS) lymphoma responding to chimeric antigen receptor (CAR) T-cell...
News
Drug receives priority review for FL
The US Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application (sBLA) for obinutuzumab (...
News
High healthcare costs follow CCSs into adulthood
New research suggests survivors of childhood cancer can incur high out-of-pocket medical costs into adulthood and may forgo healthcare to lessen...
News
Drug granted orphan designation for chemo-induced ototoxicity
The US Food and Drug Administration (FDA) has granted orphan drug designation to SENS-401 to be used for the prevention of platinum-induced...
News
Antibody could treat AML, MM, and NHL
An investigational antibody has demonstrated activity against acute myeloid leukemia (AML), multiple myeloma (MM), and non-Hodgkin lymphoma (NHL...
From the Journals
Obinutuzumab-CHOP not superior to rituximab-CHOP in new DLBCL
Two drug regimens for diffuse large B-cell lymphoma compared in a phase 3 trial.
From the Journals
Crizotinib shows responses in pediatric ALCL and IMT
Eighty percent of ALK-positive anaplastic large cell lymphoma patients in the high-dose group had a complete response, along with 83% given the...
News
New cancer diagnosis linked to arterial thromboembolism
Patients newly diagnosed with cancer may have a short-term increased risk of arterial thromboembolism, according to a new study. The research...
News
Analysis reveals poor outcomes in refractory DLBCL
Results from the SCHOLAR-1 study revealed poor outcomes of salvage therapy in patients with refractory diffuse large B-cell lymphoma (DLBCL). This...